Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome

NCT00242814 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00242814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
November 3, 2005
Completion date
Not reported
Enrollment
100 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, metabolic syndrome x